Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChiCTR2100046381Phase 4Recruiting
Phase 4, open-label, single-arm trial of pyrotinib in Non-hematologic malignancy, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and 3 more, sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Objective response rate at 6 weeks. Started Jun 2021; status: recruiting.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on ChiCTR2100046381.